A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

作者：Mahjoubi Linda^*; Gazzah Anas; Besse Benjamin; Lacroix Ludovic; Soria Jean Charles

来源：Investigational New Drugs, 2016, 34(3): 397-398.

DOI：10.1007/s10637-016-0332-0

• Crizotinib
• MET
• NSCLC
• Exon 14 mutation
• NGS

During the past decade, the treatment of lung adenocarcinomas has been revolutionized with novel molecular targeted therapies. We describe a case of clinical activity of crizotinib in a female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial response was observed in this 67 year-old woman. Further clinical trials of crizotinib are needed for non-small cell lung cancer exhibiting MET mutations.

• 出版日期2016-6